Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun;36(3):723-8.
doi: 10.1007/s10753-013-9598-y.

Association between IL-6 concentration and diabetes-related variables in DM1 patients with and without microvascular complications

Malgorzata Wegner  1 , Aleksandra Araszkiewicz, Maria Piorunska-Stolzmann, Bogna Wierusz-Wysocka, Dorota Zozulinska-Ziolkiewicz
Affiliations

Association between IL-6 concentration and diabetes-related variables in DM1 patients with and without microvascular complications

Malgorzata Wegner et al. Inflammation. 2013 Jun.

Abstract

Interleukin 6 (IL-6) plays an important role in the initiation and acceleration of chronic inflammation and could contribute to development of microvascular complications in patients with type 1 diabetes (DM1). Therefore, this study was aimed to investigate the association between concentration of IL-6 in relation to glucose control, lipid profile, and body mass index (BMI) in 69 DM1 patients subdivided according to the absence or presence of microvascular complications. BMI, level of fasting plasma glucose (FPG), and concentrations of total cholesterol (TCH), LDL cholesterol (LDL-C), and IL-6 were higher in DM1 patients compared to the control group. In DM1 patients, IL-6 concentration was positively correlated with level of FPG, LDL-C, TCH concentrations, and BMI. These correlations were stronger in the subgroup of patients with microvascular complications. In addition, BMI independently influences IL-6 concentration in DM1 patients. In conclusion, elevated IL-6 concentration is associated with diabetes-related variables which could accelerate progression of microvascular complications in DM1 patients.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
IL-6 concentration in DM1 patients without (DM) and with (DMC) microvascular complications and the control group; *p = 0.0038, statistically significant versus the control group.
See this image and copyright information in PMC

References

    1. Abi Khalil C, Roussel R, Mohammedi K, et al. Cause-specific mortality in diabetes: recent changes in trend mortality. Eur J Prev Cardiol. 2012;19:374–381. doi: 10.1177/1741826711409324. - DOI - PubMed
    1. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–820. doi: 10.1038/414813a. - DOI - PubMed
    1. Wegner M, Araszkiewicz A, Pioruńska-Mikołajczak A, et al. The evaluation of IL-12 concentration, PAF-AH, and PLA(2) activity in patients with type 1 diabetes treated with intensive insulin therapy. Clinical Biochemistry. 2009;42:1621–1627. doi: 10.1016/j.clinbiochem.2009.07.023. - DOI - PubMed
    1. Marcovecchio ML, Dalton RN, Prevost AT, et al. Prevalence of abnormal lipid profiles and the relationship with the development of microalbuminuria in adolescents with type 1 diabetes. Diabetes Care. 2009;32:658–663. doi: 10.2337/dc08-1641. - DOI - PMC - PubMed
    1. Aguiar LG, Villela NR, Bonskela E. Microcirculation in diabetes implications for chronic complications and treatment of the disease. Arg Bras Endorcrinol Metabol. 2007;51:204–211. - PubMed

LinkOut - more resources